Venue
Exchange-listed, but small. These companies file with the SEC — and have to hold on to their listing.
The company is splitting into two publicly traded businesses — one focused on insurance and pharmacy benefits, the other on retail pharmacy. Existing shareholders will own stock in both, if the separation closes as planned in 2028.
A Small Dialysis Supplier Just Agreed to Buy a Global Business Several Times Its Size
A Biotech Just Rebranded as an Italian Defense Consolidator
Pomdoctor Has Until April to Fix Two Nasdaq Deficiencies. It Hasn't Said How.
FMC Gave Up More Revenue in a Quarter Than It Booked
A Major Shareholder Wants to Take This Fitness Franchisor Private
A Failed Phase 3 Drug Shows Signs of Life in Follow-On Data
A Tiny Energy-Storage Stock Is Shrinking Its Share Count to Stay Listed
This Coffee Chain Has Until November to Convince Nasdaq It Can Stay Listed
A Convicted Founder's Claims Could Vanish Into Thin Air
A Tiny Biotech Says Its Ebola Drug Beat Remdesivir in the Lab
A Freight Broker Is Spending Tens of Millions on GPU Servers
The FDA Unblocked This Drug Trial. Nasdaq May Delist the Company Anyway.
Innventure Halves Its Own Costs and Bets Everything on One Subsidiary
A Tiny Optics Maker Just Landed Its Biggest Defense Order Ever
New Era Signed a Power Deal with Vistra. The Bill Arrives First.
One email each trading morning. Free.